Announcement of winners for the fifth “Marie Sklodowska Curie Award”

Japan Science and Technology Agency

Facebook

XLinkedInWeChatBlueskyMessageWhatsAppEmail

 

image: 

JST has selected winners for the fifth Marie Sklodowska Curie Award for young female researchers.

view more 

Credit: Japan Science and Technology Agency

The Japan Science and Technology Agency (JST) has selected winners for the Fifth Marie Sklodowska Curie Award for young female researchers.

For the Fifth Marie Sklodowska Curie Award, we accepted applications from October 1 to December 10, 2025. Through document screenings and interviews with external experts, we have selected one Grand Prize winner and two Inspiration Prize winners. In addition, considering the efforts of other applicants who meet the criteria for the award and deserve appreciation, we also selected one Recognition Prize winner.

JEOL Ltd. will award 1M yen for the Grand Prize, 500K yen for each Inspiration Prize, and 300K yen for the Recognition Prize. In addition, the Grand Prize winner will be offered an opportunity to visit research institutions in Poland—where Maria was born and raised—through the Embassy of the Republic of Poland in Japan and the Polish Academy of Sciences.

The Winners of the Fifth Marie Sklodowska Curie Award  

Grand Prize Winner

Yuko Kuroki

Data & AI Researcher, Intesa Sanpaolo AI Research (Italy)

Research field: Information Science

Inspiration Prize Winners

Ami Kobayashi

Distinguished Senior Assistant Professor (Principal Investigator), Department of Medical Science and Innovation, Institute of Medical Research, Tohoku University

Research field: Neuroscience

Sonomi Yamaguchi

HFSP Postdoctoral Fellow, Department of Cancer Immunology and Virology,  Dana-Farber Cancer Institute (United States of America)

Research field: Phage Biology, Structural Biology, Biochemistry

Recognition Prize Winner

Mariko Morimoto

Assistant Professor, Department of Chemistry and Biochemistry, University of Notre Dame (United States of America)

Research field: Chemical Biology, Immunology, Cancer Biology

 

From top left: Dr. Kuroki; top right: Dr. Kobayashi; bottom left: Dr. Yamaguchi; bottom right: Dr. Morimoto.

Credit

Japan Science and Technology Agency

About the Marie Sklodowska Curie Award

JST recognizes the importance of initiatives designed to promote the activities of female researchers in science, technology, and innovation, and based on this belief we established the “Marie Sklodowska Curie Award” in 2021, together with the Embassy of the Republic of Poland, for awarding young female researchers who are expected to flourish across the world. The award’s namesake, Dr. Marie Sklodowska Curie, was recognized for her achievements in her early thirties and later won two Nobel Prizes. The award honors her great contribution and achievements to the development of science and technology, and we hope her example will inspire the ambitions of Japanese female researchers.

While the latter half of the doctoral program and the first few years after obtaining doctoral degrees are the most promising period for female researchers to make great strides as independent researchers, it is also true that they often face various life events during this period. By honoring the achievements of the winners and making them widely recognized, we hope that this award will support them to take a leap forward with their passion and flexibility as well as to foster the next generation of female researchers.

For more information, please refer to the website.

URL: https://www.jst.go.jp/diversity/en/OurEfforts/mscaward/index.html

Five UJI researchers rank among the 300 most prominent women scientists in Spain

Marisa Salanova ranks first among women scientists from Castelló. She leads the WANT research group and focuses her research on the field of occupational health psychology

Universitat Jaume I

Facebook

BlueskyMessageWhatsAppEmail

 

image: 

The researcher Marisa Salanova, in the center, ranks first among women scientists from Castelló. She leads the WANT research group and focuses her research on the field of occupational health psychology.

Five researchers from the Universitat Jaume I of Castelló in the fields of psychology and chemistry have ranked among the top 300 Spanish and international women scientists working in Spain, according to a ranking based on public Google Scholar profiles and equivalent OpenAlex indicators.

The highest-ranked UJI researcher is Professor Marisa Salanova, while Associate Professor Isabel M. Martínez ranks third among the university’s researchers. Both carry out their research in the field of social psychology within the WANT research team on Psychosocial Prevention and Healthy Organisations at the UJI (www.want.uji.es), which in recent years has focused on occupational health psychology.

Through competitive research projects and consultancy activities for companies on psychosocial risk prevention, training and applied positive psychology, the group promotes psychosocial and financial health in organisations, as well as resilience in situations of crisis and rapid change.

The team has developed the HERO scientific model and several diagnostic tools that make it possible to assess the state of organisations and help work teams proactively and systematically plan best practices and resources to improve tasks, the social environment and organisational climate. According to Marisa Salanova, director of the research team, “this ranking helps increase the visibility of the scientific impact of the research carried out at the UJI in psychology and psychosocial health”.

Cristina Botella, founder of the Psychology and Technology Laboratory (LabPsiTec) and emeritus professor, considered the first Spanish researcher in applied psychology, together with the current laboratory director, Professor of Psychopathology Azucena García Palacios, rank second and fourth among UJI researchers. LabPsiTec investigates the possibilities that new information and communication technologies offer for clinical psychology practice.

For more than twenty-five years, the laboratory has tested tools such as virtual and augmented reality and mobile systems for clinical assessment and treatment. Professor Cristina Botella pioneered this line of work focused on different areas related to health, quality of life and personal and social wellbeing. Professor García Palacios has focused on developing intervention programmes and leading research lines devoted to personality disorders and chronic pain.

Finally, researcher María Ibáñez Martínez, from the Area of Analytical Chemistry, ranks fifth among UJI researchers. She is a member of the Public Health and Environmental Analytical Chemistry research group and the University Institute of Pesticides and Water Resources (IUPA). Her research focuses on the use of modern hybrid chromatography/mass spectrometry techniques (LC-MS), mainly high-resolution mass spectrometry (HRMS), for the control, identification, confirmation and quantification of contaminants and other organic compounds in environmental, food and biological samples. She also leads numerous GLP studies at the IUPA Pesticide Residue Analysis Laboratory.

The ranking, compiled by Isidro F. Aguillo at the Cybermetrics Lab of the Institute of Public Goods and Policies of the Spanish National Research Council (IPP-CSIC), aims to increase the visibility of women researchers through open-access platforms such as Google Scholar, ORCID and OpenAlex, which provide broader coverage than other bibliometric sources, including subscription-based databases. It also seeks to promote open infrastructures through the wider use of personal ORCID identifiers and institutional ROR identifiers.

The 2026 edition of the ranking includes a total of 12,110 researchers ranked according to the global impact of their research, 122 of whom belong to the public university of Castelló. The full ranking can be consulted in the author’s publication.

Publication

Aguillo, Isidro F. (2026). Ranking de mujeres investigadoras españolas y en España. Edición GS-ORCID OPENALEX Abril 2026. figshare. Preprint. https://doi.org/10.6084/m9.figshare.32063853.v5

view more 

Credit: Universitat Jaume I of Castellón

Five researchers from the Universitat Jaume I of Castelló in the fields of psychology and chemistry have ranked among the top 300 Spanish and international women scientists working in Spain, according to a ranking based on public Google Scholar profiles and equivalent OpenAlex indicators.

The highest-ranked UJI researcher is Professor Marisa Salanova, while Associate Professor Isabel M. Martínez ranks third among the university’s researchers. Both carry out their research in the field of social psychology within the WANT research team on Psychosocial Prevention and Healthy Organisations at the UJI (www.want.uji.es), which in recent years has focused on occupational health psychology.

Through competitive research projects and consultancy activities for companies on psychosocial risk prevention, training and applied positive psychology, the group promotes psychosocial and financial health in organisations, as well as resilience in situations of crisis and rapid change.

The team has developed the HERO scientific model and several diagnostic tools that make it possible to assess the state of organisations and help work teams proactively and systematically plan best practices and resources to improve tasks, the social environment and organisational climate. According to Marisa Salanova, director of the research team, “this ranking helps increase the visibility of the scientific impact of the research carried out at the UJI in psychology and psychosocial health”.

Cristina Botella, founder of the Psychology and Technology Laboratory (LabPsiTec) and emeritus professor, considered the first Spanish researcher in applied psychology, together with the current laboratory director, Professor of Psychopathology Azucena García Palacios, rank second and fourth among UJI researchers. LabPsiTec investigates the possibilities that new information and communication technologies offer for clinical psychology practice.

For more than twenty-five years, the laboratory has tested tools such as virtual and augmented reality and mobile systems for clinical assessment and treatment. Professor Cristina Botella pioneered this line of work focused on different areas related to health, quality of life and personal and social wellbeing. Professor García Palacios has focused on developing intervention programmes and leading research lines devoted to personality disorders and chronic pain.

Finally, researcher María Ibáñez Martínez, from the Area of Analytical Chemistry, ranks fifth among UJI researchers. She is a member of the Public Health and Environmental Analytical Chemistry research group and the University Institute of Pesticides and Water Resources (IUPA). Her research focuses on the use of modern hybrid chromatography/mass spectrometry techniques (LC-MS), mainly high-resolution mass spectrometry (HRMS), for the control, identification, confirmation and quantification of contaminants and other organic compounds in environmental, food and biological samples. She also leads numerous GLP studies at the IUPA Pesticide Residue Analysis Laboratory.

The ranking, compiled by Isidro F. Aguillo at the Cybermetrics Lab of the Institute of Public Goods and Policies of the Spanish National Research Council (IPP-CSIC), aims to increase the visibility of women researchers through open-access platforms such as Google Scholar, ORCID and OpenAlex, which provide broader coverage than other bibliometric sources, including subscription-based databases. It also seeks to promote open infrastructures through the wider use of personal ORCID identifiers and institutional ROR identifiers.

The 2026 edition of the ranking includes a total of 12,110 researchers ranked according to the global impact of their research, 122 of whom belong to the public university of Castelló. The full ranking can be consulted in the author’s publication.

Publication

Aguillo, Isidro F. (2026). Ranking de mujeres investigadoras españolas y en España. Edición GS-ORCID OPENALEX Abril 2026. figshare. Preprint. https://doi.org/10.6084/m9.figshare.32063853.v5

---

DOI

10.6084/m9.figshare.32063853.v5 

Gladstone launches Center for PhAIge Therapy to harness AI in the fight against drug-resistant infections

The center, funded by an NIH grant, will become one of three national centers dedicated to accelerating the development of phage therapy.

Gladstone Institutes

Facebook

X
BlueskyMessageWhatsAppEmail

 

image: 

A team of scientists at Gladstone Institutes—including Katie Pollard (left), Melanie Ott (center), Seth Shipman (right), and Sukrit Silas (absent from the photo)—will lead one of three new national centers dedicated to accelerating the development of phage therapy.

view more 

Credit: Photo: Michael Short/Gladstone Institutes

SAN FRANCISCO—When a bacterial infection stops responding to antibiotics, doctors have few options to treat it. Phages—viruses that naturally infect and kill bacteria—have long intrigued clinicians as a potential weapon against these infections. But translating these tiny bacteria hunters into drugs has been slow and unreliable.

Now a new effort, powered by engineering and artificial intelligence, could change that.

Gladstone Institutes has received an initial award of $2 million from the National Institute of Allergy and Infectious Diseases (NIAID), with additional funding of up to a total of $10 million available over the proposed 5-year project period. This grant will establish the Center for PhAIge Therapy, a research center that will develop new phage-based treatments for antibiotic-resistant bacterial infections.

The five-year grant makes Gladstone one of three institutions across the country selected to lead this coordinated effort. Together, the new Centers for Accelerating Phage Therapy to Combat ESKAPE Pathogens (CAPT-CEP) will advance the therapeutic use of phages.

The Center for PhAIge Therapy will be directed by Gladstone Investigator Seth Shipman, PhD, with projects and core components led by an interdisciplinary team of other Gladstone scientists.

“Phages have the potential to treat drug-resistant infections, but for patients to benefit from that potential, we need to be able to predict which phage to use for which patient, and design phages that are more effective than what we have today,” says Shipman. “That’s what this center is designed to do.”

Tackling Critical Threats to Modern Medicine

Every year, about 5 million deaths around the world are associated with antibiotic-resistant infections.

People with weakened immune systems, including those with cancer who are receiving immune therapies, are particularly vulnerable because they rely heavily on effective antibiotics. But antibiotic resistance is no longer confined to high-risk patients—it’s increasingly affecting the broader hospital population as well.

Among the leading causes of these deaths are major hospital “superbugs” called the ESKAPE pathogens—Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species.

These bacterial species appear on the World Health Organization’s list of priority pathogens. They are considered critical threats to modern medicine not only because they resist drugs, but they swap defense mechanisms and quickly adapt after being exposed to new antibiotics.

Given that phages have evolved the ability to kill bacteria in distinct and targeted ways, they have attracted growing interest as a potential weapon against ESKAPE pathogens and other antibiotic-resistant infections.

So far, despite promising results in individual patients, phage therapy has remained difficult to use at a larger scale, in part because it has required so much trial and error for each patient.

The new Center for PhAIge Therapy will build the preclinical tools and models needed to overcome this obstacle and make phages a more reliable treatment for infections.

Gladstone scientists have developed AI tools to predict which phages can work against a particular strain of bacteria, but the models are lacking the right data to make the predictions accurate. So, the researchers will run massive experiments using engineered phages and bacteria to better understand, step by step, how bacteria are killed.

“The goal of our center is to generate an unprecedented amount of data and train AI models to identify the right phage for any patient’s infection,” says Shipman.

Deploying Phages Against Drug-Resistant Pathogens

Shipman’s lab has already developed tools to precisely edit phage genomes in a highly effective way, giving them the ability to engineer new phages.

The Center for PhAIge Therapy will allow the team to build on that technology and develop new tools to accelerate research on how best to optimize and deploy phages against ESKAPE pathogens.

They will build high-throughput assays to measure how individual parts of phages contribute to their activity against bacteria. The project will ultimately generate the data needed to rationally design and select phages effective against Klebsiella pneumoniae.

In healthcare settings, Klebsiella pneumoniae can cause serious infections—including pneumonia, bloodstream infections, and meningitis—among patients on ventilators or intravenous catheters. These bacteria are becoming increasingly resistant to antibiotics, even the last lines of defense used against bacterial infections, and drive over 600,000 deaths per year.

In parallel to Shipman’s work, Gladstone Investigator Sukrit Silas, PhD, will characterize how Klebsiella pneumoniae strains vary in their susceptibility to phages, with the goal of identifying phage combinations most likely to work against specific strains.

Powering both projects will be close collaborations with Katie Pollard, PhD, director of the Gladstone Institute of Data Science and Biotechnology, and Melanie Ott, MD, PhD, director of the Gladstone Infectious Disease Institute.

Pollard will lead the development of new algorithms to predict the compatibility of phage-bacteria pairs and to optimize natural phages into drugs. Using human lung organoids that more closely mimic human tissues than traditional animal models, Ott’s team will study how the body’s environment impacts phage behavior and treatment outcomes, something that can’t be captured in conventional laboratory models.

“What excites me about this collection of projects is that we’re creating a system where the data and the AI build off each other with each iteration,” says Shipman. “We’re not just studying phages using the same methods as in the past; we’re making an infrastructure to rationally predict how we can use phages with success in the future.”

In addition to the Gladstone Center for PhAIge Therapy, the CAPT-CEP network will also be supporting the Center for Phage Pharmaceuticals at Stanford University, which will focus on phage delivery to the lung, and the Pitt Center for Accelerating Phage Therapy at the University of Pittsburgh, which will develop assays for designing and dosing phage cocktails for patients. The three centers will share assays, materials, and data.

###

About the Grant

The Center for PhAIge Therapy at Gladstone will receive $10,239,795 over five years from the National Institute of Allergy and Infectious Diseases (NIAID), as part of the Centers for Accelerating Phage (Bacteriophage) Therapy to Combat ESKAPE Pathogens (CAPT-CEP). The grant P01AI195327 was awarded as a result of the funding call RFA-AI-24-069.

About Gladstone Institutes

Gladstone Institutes is an independent, nonprofit life science research organization that uses visionary science and technology to overcome disease. Established in 1979, it is located in the epicenter of biomedical and technological innovation, in the Mission Bay neighborhood of San Francisco. Gladstone has created a research model that disrupts how science is done, funds big ideas, and attracts the brightest minds.

 

Protection for newborns: New treatment aims to prevent meningitis without antibiotics

ETH Zurich

Facebook

XLinkedInWeChatBlueskyMessageWhatsAppEmail

Newborn meningitis is one of the most dangerous childhood infections. It is often life-threatening and can cause serious and lasting damage, including developmental problems, in the children who survive. Although meningitis is thankfully rare in newborns as a whole, it is more common in premature babies, affecting one in every 500 such infants in industrialised economies and likely more in developing countries.

One of the leading pathogens responsible for these meningitis cases is the K1 form of the E. coli bacterium. Now, researchers from ETH Zurich and the University of Basel have developed an approach that seeks to prevent transmission to newborns.

To understand this approach, we need to start in the adult intestine: in one in three healthy adults, E. coli K1 is part of the intestinal flora. As a silent cohabitant, the bacterium causes no problems in this environment. It is kept in check by other bacteria and a functioning immune system.

However, if the pathogen is carried by an expectant mother, it can be transmitted to the child during birth and enter its intestine. In premature babies whose immune systems are still weak, the pathogen can enter the bloodstream and migrate to the brain, where it causes severe inflammation.

First weaken the pathogen, then fight it

Researchers led by Emma Slack, Professor of Mucosal Immunology at ETH Zurich, and Médéric Diard, Professor of Infection Biology at the Biozentrum of the University of Basel, want to stop transmission from happening in the first place. Their idea is to eliminate the pathogen in pregnant women who carry it in their intestine – but that’s easier said than done.

A year ago, the two researchers from Zurich and Basel had already jointly developed a concept for eradicating other pathogens living in the intestine (as ETH News reported). Back then, they used a combination therapy with two components: an oral vaccination that weakens the pathogenic bacterium, followed by a dose of harmless microbes that compete with the weakened pathogen for food, starve it out, and ultimately supersede it. In experiments on mice, the researchers demonstrated that this approach can eliminate certain salmonellas and E. coli strains in the intestine.  

So tough that three components are needed

However, the K1 form of E. coli is a formidable opponent: unlike other E. coli bacteria, it is protected by a slippery outer layer. This prevents the antibodies generated by the oral vaccination from attacking the bacterium.

The team of researchers led by Slack and Diard therefore extended its previous two-pronged approach with a third component known as bacteriophages (or simply phages). These are viruses that specifically infect and kill bacteria.

However, the bacteria can make changes to themselves in order to evade the danger posed by these viruses. The phages attack the bacteria by docking to the protective layer, and the bacteria seek to prevent this by undergoing a sort of rapid evolution in which this layer is disposed of. Rapid in this case means that, since the bacteria are so numerous and multiply so quickly, they need fewer than 24 hours to adapt. 

“This is essentially a resistance mechanism that the bacteria deploy against the phages,” says Slack. “We use this mechanism to our advantage: the antibodies formed by the oral vaccination are effective against K1 bacteria that no longer have their protective coating.”

Most young animals protected

The project involved searching for effective strains of phages. Scientists generally find phages in places that are home to lots of bacteria: nutrient-rich bodies of water, the intestinal flora or, very often, waste water and waste water treatment plants. When it comes to the phages used in this study, the researchers from the Biozentrum in Basel found what they were looking for in waste water samples from the treatment plant of the Lucerne conurbation. From such a sample, their lab work successfully isolated several phages that are particularly effective at attacking the bacterium E. coli K1.

In experiments with pregnant mice, which the researchers had previously infected with pathogenic E. coli K1, they were able to demonstrate the effectiveness of their triple-pronged treatment. The researchers first gave the mice phages that forced the bacteria to cast off their protective shell. Second, they administered an oral vaccination that produced antibodies in the intestine in order to weaken the bacteria. Third, they gave them a harmless probiotic bacterium that could compete against the weakened bacteria and occupy their ecological niche in the intestine.

In a control experiment in which the researchers did not treat the mothers, E. coli K1 was transmitted to 83 percent of young animals at birth. By contrast, the triple-pronged treatment significantly reduced the level of E. coli K1 in the mothers’ intestines, such that the pathogen was only transmitted to 23 percent of the young animals. The remaining offspring were protected.

Works even when antibiotics fail

The researchers are now keen to continue with their approach in order to develop a treatment for humans. In a world in which effective antibiotics are becoming increasingly scarce, we need new therapeutic approaches, says Slack. “Bacteria such as E. coli K1 are difficult to tackle. Our approach is potentially the only one that can be used to fight this pathogen and others without antibiotics.”

Not only can E. coli K1 cause cases of meningitis in newborns, which today must be treated with antibiotics in a race against time. It is also one of the most frequent causes of cystitis and pyelitis – infections that can also lead to serious cases of sepsis. 

The ETH professor doesn’t perceive any major obstacles to developing an effective treatment for humans: “Oral vaccinations, probiotics and even phages are all already used in medicine,” she says. It will also be possible, she adds, to pack all three components into a single capsule that people can simply swallow.

Moreover, the scientists are planning projects in which they want to use the same approach to tackle bacteria other than E. coli K1, including multi-resistant pathogens, against which many antibiotics are no longer effective.

This research project was supported by the Basel Research Centre for Child Health. 

---

Journal

Nature Communications

DOI

10.1038/s41467-026-70808-2 

Article Title

Phage-steering permits antibody-mediated clearance of E. coli K1 from the gut

 

Establishing a regulatory framework for phage therapy in China

SciOpen

LinkedInWeChat
WhatsAppEmail

 

image: 

Current situation and proposed future regulatory frameworks for phage therapy in China. Phage therapy was initially conducted as IITs in China. In May 2026, State Council Decree No. 818 introduced the anticipated clinical translation of phage therapy as a new biomedical technology. In the future, phage therapy in China may be developed through two pathways: as a pharmaceutical product or as a new biomedical technology. Clearer and more science-based regulatory frameworks need to be established through collaborative efforts among regulatory authorities, academia, and industry.

view more 

Credit: hLife

With antimicrobial resistance (AMR) projected to cause more than 39 million deaths and trillions of dollars in economic losses between 2025 and 2050, phage therapy is emerging as a critical solution. In China, phage therapy has already been used across more than 30 hospitals to treat over 500 patients with drug-resistant infections. However, the country currently lacks a dedicated regulatory framework to guide its full clinical translation.

Global phage therapy regulatory frameworks diverge. The European Union (EU, led by Belgium) uses a flexible magistral preparation model, enabling low‑cost, personalized phage therapy without formal drug approval. Meanwhile, the US regulates phages as biologics and provides access via emergency Investigational New Drug (IND) pathways. The UK allows the import of unlicensed products for compassionate use, while Australia is piloting a three‑year GMP exemption for small‑batch, personalized products. Georgia has a long history of phage use but lacks GMP‑compliant production, limiting international acceptance.

In China, phage therapy commenced under investigator‑initiated trial regulations in 2018. Recent policy signals are encouraging: a 2025 NMPA draft guidance indicates that gene‑edited phages may be classified as advanced therapy medicinal products (ATMPs), and State Council Decree No. 818 (effective May 2026) introduces a filing mechanism for phage therapy as a new biomedical technology. Nevertheless, national quality standards and clear approval pathways remain absent.

The research team advocates a three-pillared approach: "standards first, pathway pilots, and industry cultivation." Key recommendations include: (1) National quality guidelines: Develop a technical guideline for phage preparation quality control, building on an existing Shanghai group standard, TSHPPA 028-2024, and ISO/TS 20853:2026. (2) Phase‑appropriate GMP pilot: Offer a 2–3 year GMP exemption or simplified certification for personalized, low‑risk phage preparations that address urgent clinical needs, allowing qualified hospitals to produce them under ethical review while building GMP capacity. (3) Clear product classification: Specify that standard phage products follow the biologics pathway, while gene‑edited phage products may qualify for ATMP classification with expedited policies. (4) Regional centers and reimbursement: Authorize experienced hospitals to establish regional phage therapy centers, supported by integrated pricing, health insurance, and commercial insurance mechanisms.

Dr. Shuai Le emphasizes that comprehensive international frameworks for phage therapy remain underdeveloped. China now has a pivotal opportunity to transition from a regulatory follower to a global frontrunner. By building a high‑quality, context‑appropriate development pathway, China can advance its “Healthy China” initiative while contributing meaningfully to the global fight against AMR.

This research was completed by a joint team from Army Medical University, The Forsyth Institute, CreatiPhage Biotechnology Co., Ltd., and Fudan University. This work was supported by grants from the National Key Research and Development Program of China (2021YFA0911200 to S.L.).

 

About Author:

Shuai Le, Associate Professor at Army Medical University. His laboratory specializes in deciphering the evolutionary battle between phages and their hosts while advancing synthetic phage design and clinical optimization, bridging the gap between basic research and therapeutic applications. A key milestone in his career includes co-leading China’s first personalized trial and first RCT clinical trial on bacteriophage therapy, establishing a foundation for evidence-based phage medicine in the country. Dr. Le has authored over 50 SCI-indexed publications in top-tier journals, including Nature Microbiology, PNAS, The EMBO Journal, and hLife.

---

Journal

hLife

DOI

10.1016/j.hlife.2026.05.001 

Article Title

Establishing a Regulatory Framework for Phage Therapy in China

Article Publication Date

12-May-2026